Articles
Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background
Sep 1, 2023 |
cell.com | Cong Zhang |Novartis Institutes |Konstantin Shestopaloff |Benjamin Hollis
SummaryResponse to the anti-IL17 monoclonal antibody secukinumab is heterogeneous, and not all participants respond to treatment. Understanding whether this heterogeneity is driven by genetic variation is a key aim of pharmacogenetics and could influence precision medicine approaches in inflammatory diseases.
-
Jan 9, 2022 |
documentaryweekly.com | Benjamin Hollis
-
Oct 23, 2020 |
documentaryweekly.com | Benjamin Hollis
-
Oct 17, 2020 |
documentaryweekly.com | Benjamin Hollis
-
Oct 8, 2020 |
mydylarama.org.uk | Benjamin Hollis
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →